The effects of modified cyclodextrins (CDs) hydroxypropyl--CD and methyl--CD were studied in vitro on cDNA-expressed human cytochrome P-450 (CYP) activities (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). The modified CDs inhibited the activities of CYP2C19 and CYP3A4 while enhancing CYP2C9 activity by 140 to 176% relative to the control values at lower concentrations. In addition, methyl--CD inhibited CYP1A2 and CYP2D6 at higher concentrations.
Cytochromes P-450 (CYP) are principal enzymes for the oxidation of drugs, environmental pollutants, and other xenobiotics. The enzyme system exists in many distinct forms of the enzyme. All mammalian forms are membrane-bound and found in many tissues, but at the highest levels in the liver. A principal function of the CYP system is to convert lipophilic molecules into more water-soluble forms, which are more readily excreted from the body.
Because of the lipophilic nature of many CYP substrates, organic solvents are often required for solubilization of the substrate during in vitro incubation. Several analyses of solvent inhibition have been reported. Chauret et al., 1) Hickman et al., 2) and Busby et al. 3) have reported the effects of several organic solvents on enzyme-selective activities in human liver microsomes, but the potential influence of these solvents on CYP activities has not been adequately studied. A number of insoluble (or poorly soluble) compounds and drugs can be dissolved in an aqueous solution of hydroxypropyl--CD (HP--CD) or randomly substituted methyl--CD (Me--CD), which are modified forms of cyclic oligosaccharides derived from starch. The demand for modified CD solution as a solvent of insoluble drugs has increased in recent years. [4] [5] [6] Hence it is important to study the effect of modified CD solution as a solvent on the metabolism of structurally diverse CYP substrates, to estimate its influence on the in vitro CYP reaction, and to formulate a hypothesis for the interaction mechanism.
In the present study, we investigated the interactions of two commonly used modified CD solutions, aqueous solutions of HP--CD and Me--CD, on substrate metabolism by the hepatic forms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
HP--CD (degree of substitution DS = 5.15) was a gift from Nihon Shokuhin Kako (Tokyo, Japan), and Me--CD (DS ¼ 1:6{1:9) was obtained from Wacker Chemie (Munich, Germany). cDNA-expressed CYP isoforms and their substrates, such as 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-methoxy-4-trifluoromethylcoumarin (MFC), and 7-ethoxy-3-cyanocoumarin (CEC) were obtained from BD Gentest (Woburn, MA, U.S.A.).
An in vitro fluorometric microtiter plate assay 7) has been adapted and modified by Crespi et al. 8, 9) Assays were conducted in 96-well microplates. One tenth of a ml of potassium phosphate buffer solution (pH 7.4) including modified CDs (0.2-20 mM of final concentration) containing an NADPH-regenerating system was added to each well. The final concentrations were 1.3 mM NADP þ , 3.3 mM glucose-6-phosphate, and 0.4 U/ml glucose-6-phosphate dehydrogenase. The plate was then warmed to 37 C and the reaction initiated by the addition of pre-warmed enzyme/substrate (E/S) mixture, which contained the buffer, CYP enzyme, substrate, and a control microsome. The final concentration of the control microsomal protein was set to 100 mg-protein/ml. Wells 9 and 10 contained no modified CDs, and wells 11 and 12 were controls for background fluorescence in which enzyme and substrate were added after the reaction was terminated. Incubations were carried out for each CYP under the conditions shown in Table 1 , and the reaction was stopped by the addition of 0.06 ml of 80% acetonitrile-20% 0.5 M Tris base. The metabolite of each substrate and the excitation or emission wavelength for measurement are listed in Table 1 . The fluorescence signal was measured using a fluorescence plate reader (Spectra Fluor Plus, Tecan Japan, Tokyo, Japan). Table 1 shows the assay parameters routinely used in our laboratory. All samples were prepared in duplicate. The percentage inhibition was evaluated based on the mathematical combinations for the differences in fluorescence between the test/testblank wells and the mean reference between each control and blank well. Controls were run with every assay. Each assay was repeated at least twice. Data were analyzed by a one-way ANOVA for each isozyme, followed by a pairwise comparison utilizing Dunnett's test. Analytical results were exported and analyzed using an Excel spreadsheet or Pharmacokinetic parameter software WinNonlin Ò (Pharsight, NC, U.S.A.). the IC 50 value was defined as the inhibitor concentration (in mM) at which fluorescence was 50% compared to the control value, and was also determined graphically.
The effects of HP--CD and Me--CD on the catalytic activities of five human cDNA-expressed CYP isoforms are shown in Fig. 1 . Experiments were performed at modified CD concentration ranges of 0.2 to 20 mM. HP--CD markedly increased CYP2C9 activity, up to 140% relative to the control value, at concen- trations less than 3 mM, showing a slight induction period. However, for CYP1A2 and CYP2D6, no enhancement of activities was found during the induction period, but there were no inhibitions at higher concentrations. Strong inhibitions were observed for CYP2C19 (IC 50 : 6.81 mM) and CYP3A4 (IC 50 : 2.68 mM) in the HP--CD concentration range between 0.2 and 20 mM. Me--CD also increased CYP2C9 activity up to 176% above the control value, while for CYP1A2 and CYP2D6, an induction period was observed analogous to that of HP--CD, and was markedly inhibited at high concentrations, above 10 mM. In addition, rather strong inhibitory effects to CYP2C19 (IC 50 : 6.45 mM) and CYP3A4 (IC 50 : 0.69 mM) were observed.
In the present study, it can be concluded that both HP--CD and Me--CD show an induction period to CYP2C9, CYP1A2, and CYP2D6 activity at lower concentrations. Similar phenomena of slight increases in CYP2C9 reaction have been reported for both acetone and asetonitrile as organic solvent. [1] [2] [3] We have confirmed those original findings and report that both acetone and acetonitrile interact with the substrate metabolism, a reaction mediated primary by CYP2C9. The extent of increase in CYP2C9 activity in our reaction system was of the same magnitude as that was previously observed by other investigators.
1-3) Possible reasons for this increase might be the modification of the physico-pharmaceutical properties of CYP2C9 substrate (MFC) and its components through the formations of inclusion of complex by modified CDs. Alternatively, it might be due to the enhanced fluidity of the membrane components as this facilitates some sort of a protein/ protein type interaction between CYP2C9 with CYP reductase and/or cytochrome b 5 . 8) In addition, at lower concentrations of modified CDs, especially the HP--CD, there was little influence on the CYP activity except for CYP2C19 and CYP3A4. Hence it is suggested that an aqueous solution of HP--CD is an excellent solvent compared with the organic solvent. On the other hand, the Me--CD tested inhibited all CYP substrate metabolisms at the higher concentrations. This is probably due to biophysical disruption of the CYP membrane, because Me--CD is relatively stimulatory and of low toxicity. 10, 11) 
